Charles Schwab Investment Management Inc. Has $18.43 Million Stock Position in Sotera Health (NASDAQ:SHC)

Charles Schwab Investment Management Inc. decreased its stake in Sotera Health (NASDAQ:SHC) by 0.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,347,195 shares of the company’s stock after selling 1,722 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.48% of Sotera Health worth $18,430,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of SHC. Victory Capital Management Inc. boosted its position in Sotera Health by 25.7% during the 3rd quarter. Victory Capital Management Inc. now owns 32,610 shares of the company’s stock worth $545,000 after acquiring an additional 6,666 shares during the period. Mutual of America Capital Management LLC boosted its position in Sotera Health by 15.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 82,654 shares of the company’s stock worth $1,380,000 after acquiring an additional 11,342 shares during the period. Thrivent Financial for Lutherans boosted its position in Sotera Health by 19.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 35,929 shares of the company’s stock worth $600,000 after acquiring an additional 5,835 shares during the period. Sessa Capital IM L.P. boosted its position in Sotera Health by 46.5% during the 3rd quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares during the period. Finally, Cerity Partners LLC acquired a new stake in Sotera Health during the 3rd quarter worth about $1,489,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SHC. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on Sotera Health in a research note on Friday, December 6th. They set a “neutral” rating and a $14.00 price target for the company. Finally, Barclays cut their price target on Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and an average target price of $15.92.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $12.24 on Thursday. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The business’s 50 day moving average is $12.99 and its two-hundred day moving average is $14.19. The company has a market cap of $3.47 billion, a P/E ratio of 48.96 and a beta of 1.92. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.